(210 days)
No
The device description and performance studies focus on mechanical and material properties, with no mention of AI or ML.
No
The device is a Closed System Drug Transfer Device (CSTD) designed to safely prepare and administer hazardous drugs by minimizing exposure to healthcare personnel and preventing contamination, rather than directly treating a medical condition itself.
No
Explanation: The device is a Closed System Drug Transfer Device (CSTD) designed to safely reconstitute and transfer hazardous drugs, preventing exposure to individuals and the environment. Its primary function is to manage drug preparation and administration, not to diagnose medical conditions.
No
The device description clearly outlines multiple physical components made of materials like polymeric tubing and mentions performance tests related to mechanical properties and leakage, indicating it is a hardware device.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is a "Closed System Drug Transfer Device (CSTD)" used for the "preparation and administration" of drugs, specifically hazardous drugs. It focuses on preventing exposure to these drugs and maintaining sterility.
- Device Description: The description details a system for reconstituting and transferring drugs into infusion bags, bottles, or syringes. The new component, the Catheter Adaptor, facilitates the administration of cytotoxic drugs to the bladder.
- Lack of Diagnostic Function: There is no mention of the device being used to examine specimens from the human body to provide information for the diagnosis, prevention, or treatment of disease. It is purely a drug handling and administration system.
Therefore, the TEVADAPTOR® system, including the new Catheter Adaptor, falls under the category of a medical device used for drug delivery and safety, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
TEVADAPTOR is a Closed System Drug Transfer Device (CSTD) that mechanically prohibits the release of the drug in vapor, aerosol or liquid form during preparation and administration, and prevents the introduction of microbial and airborne contaminants into the drug or fluid path, allowing the system to minimize exposure of individuals, healthcare personnel, and the environment to hazardous drugs.
Product codes (comma separated list FDA assigned to the subject device)
ONB
Device Description
The TEVADAPTOR® Closed Drug Reconstitution and Transfer System is a system of components that allows the safe reconstitution of liquid or pre-dissolved powder drugs into infusion bags, flexible bottles or syringes. Single, partial or multiple vials can be used for each infusion solution container. The TEVADAPTOR® Closed Drug Reconstitution and Transfer System prevents contamination of the user or the environment by the drug through the use of elastomeric seals and an active carbon filter. Sterility of the drug in the vial is maintained because any air entering the vial during pressure equalization enters through of a hydrophobic acrylic copolymer membrane with a pore size of 0.2 micron.
The components of the previously cleared TEVADAPTOR® system are:
- . Vial Adaptor 20 mm with 13 mm Vial Converter
- . Vial Adaptor 28 mm
- . Syringe Adaptor
- Spike Port Adaptor .
- . Connecting Set
- . Luer Lock Adaptor
- . Syringe Adaptor Lock
Each of the above component parts is available separately.
The purpose of this 510(k) is to add an additional component to the TEVADAPTOR® system already cleared for sale in the US, the description of which is:
- New component: TEVADAPTOR® Catheter Adaptor
The Catheter Adaptor provides closed system protection and disconnection of the fluid path between the Syringe Adaptor of the TEVADAPTOR® system and a bladder catheter (not supplied), while allowing safe administration of cytotoxic drugs to the bladder.
The Catheter Adaptor connects to the TEVADAPTOR® Syringe Adaptor, the short length of polymeric tubing of the adaptor is connected to the adaptor main body, which in turn is connected to the universal bladder catheter connector. A vented cap is supplied over the universal connector. The universal bladder catheter connector connects to a bladder catheter (not supplied).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Reconstitute and transfer antineoplastic and other hazardous drugs in healthcare setting indicated to reduce exposure of healthcare personnel to chemotherapy agents in healthcare setting.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance tests have been conducted on both non-aged samples that have been aged for 12 months following routine sterilization.
These tests included:
- Air leakage test to demonstrate that there is no leakage between the connections of the Catheter Adaptor components under an air pressure of 0.7 bar for at least 15 min. No failures observed at T0 and T12mo.
- . Catheter Adaptor component disconnection force test – to demonstrate that the disconnection force between the component connections shall not be less than 3.00 kgf at a speed of 500 mm/min and shall have a gluing depth of 8.0 mm. No failures observed at T0 and T12mo.
- Catheter Adaptor component unclogged device test to demonstrate that air bubbles appear in the water bath for at least 15 min. No failures observed at T0 and T12mo.
- Non-Luer universal connector to a bladder catheter to demonstrate that the connection . between the non-Luer universal connector of the Catheter Adaptor and the bladder catheter is sealed to prevent user exposure to hazardous drugs. Testing was carried out in accordance with ISO 8536-4:2010, section 6.11.
- . Chemical resistance test - to demonstrate that the device is compatible with cytotoxic drugs.
In addition, biocompatibility tests have been carried out on the components of the Catheter Adaptor to demonstrate that the three new materials used meet the requirements of ISO 10993 and FDA guidance.
Key results: No failures observed in the air leakage test, disconnection force test, and unclogged device test at T0 and T12mo. The connection to the bladder catheter was sealed. The device was demonstrated to be compatible with cytotoxic drugs. Biocompatibility tests of new materials met ISO 10993 and FDA guidance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration (FDA). The Department of Health and Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and the word "ADMINISTRATION" in a smaller font below. The logos are placed side-by-side.
September 21, 2018
Teva Medical Ltd., Migada Plant % Roger Gray VP Quality and Regulatory Donawa Lifescience Consulting Piazza Albania 10 Rome, 00153 ITALY
Re: K180489
Trade/Device Name: TEVADAPTOR® Closed Drug Reconstitution and Transfer System Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular administration set Regulatory Class: Class II Product Code: ONB Dated: August 14, 2018 Received: August 16, 2018
Dear Roger Gray:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely, Tina Kiang
Tina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180489
Device Name
TEVADAPTOR Closed Drug Reconstitution and Transfer System
Indications for Use (Describe)
TEVADAPTOR is a Closed System Drug Transfer Device (CSTD) that mechanically prohibits the release of the drug in vapor, aerosol or liquid form during preparation and administration, and prevents the introduction of microbial and airborne contaminants into the drug or fluid path, allowing the system to minimize exposure of individuals, healthcare personnel, and the environment to hazardous drugs.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for Teva Medical. The logo is divided into two sections, with the left section containing the word "TEVA" in a stylized font and a light blue color. The right section is green and contains the word "Medical" in a white, sans-serif font, with the text "Teva Medical Ltd." below it in a smaller font.
510(k) Summary in accordance with 21 CFR 807.92(c) (K180489)
| Device Name: | TEVADAPTOR® Closed Drug Reconstitution and Transfer System |
|---|---|
| Type of 510(k) submission: | Traditional |
| Date of Submission: | 10 September 2018 |
| Manufacturer: | Teva Medical Ltd., MIGADA Plant, North Industrial Zone Kiryat Shmona, 10258 ISRAEL |
| FDA Registration Number: | 9611423 |
| Owner/Operator Number: | 9001925 |
| 510(k) Owner & Submitter: | Teva Medical Ltd., MIGADA Plant North Industrial Zone Kiryat Shmona, 10258 ISRAEL |
| Phone: | +972-4-6908826 |
| Fax: | +972-9-892-1659 |
| 510(k) Application Correspondent: | Mr Roger Gray |
| VP Quality and Regulatory | |
| Donawa Lifescience Consulting | |
| Piazza Albania 10, 00153 Rome Italy | |
| Phone: | +39 06 578 2665 |
| Fax: | +30 06 574 3786 |
| Email: | rgray@donawa.com |
| FDA Product Code: | ONB |
| FDA Regulation Number: | 880.5440 |
| FDA Regulation Name: | Intravascular administration set |
| Classification Panel: | General Hospital |
| Common Name: | Closed Drug Reconstitution and Transfer System |
| FDA Classification: | Class II |
| FDA Identification: | Reconstitute and transfer antineoplastic and other hazardous drugs in healthcare setting indicated to reduce exposure of healthcare personnel to chemotherapy agents in healthcare setting. |
Indications for Use: TEVADAPTOR® is a Closed System Drug Transfer Device (CSTD) that mechanically prohibits the release of the drug in vapor, aerosol or liquid form during preparation and administration, and prevents the introduction of microbial and airborne contaminants into the drug or fluid path, allowing the system to minimize exposure of individuals, healthcare personnel, and the environment to hazardous drugs.
Device Description:
The TEVADAPTOR® Closed Drug Reconstitution and Transfer System is a system of components that allows the safe reconstitution of liquid or pre-dissolved powder drugs into infusion bags, flexible bottles or syringes. Single, partial or multiple vials can be used for each infusion solution container. The TEVADAPTOR® Closed Drug Reconstitution and Transfer System prevents contamination of the user or
4
Image /page/4/Picture/0 description: The image shows two logos side by side. The first logo on the left is for TEVA and is in a light blue color. The second logo on the right is for Teva Medical Ltd. and is in green with white text.
the environment by the drug through the use of elastomeric seals and an active carbon filter. Sterility of the drug in the vial is maintained because any air entering the vial during pressure equalization enters through of a hydrophobic acrylic copolymer membrane with a pore size of 0.2 micron.
The components of the previously cleared TEVADAPTOR® system are:
- . Vial Adaptor 20 mm with 13 mm Vial Converter
- . Vial Adaptor 28 mm
- . Syringe Adaptor
- Spike Port Adaptor .
- . Connecting Set
- . Luer Lock Adaptor
- . Syringe Adaptor Lock
Each of the above component parts is available separately.
The purpose of this 510(k) is to add an additional component to the TEVADAPTOR® system already cleared for sale in the US, the description of which is:
- New component: TEVADAPTOR® Catheter Adaptor
The Catheter Adaptor provides closed system protection and disconnection of the fluid path between the Syringe Adaptor of the TEVADAPTOR® system and a bladder catheter (not supplied), while allowing safe administration of cytotoxic drugs to the bladder.
The Catheter Adaptor connects to the TEVADAPTOR® Syringe Adaptor, the short length of polymeric tubing of the adaptor is connected to the adaptor main body, which in turn is connected to the universal bladder catheter connector. A vented cap is supplied over the universal connector. The universal bladder catheter connector connects to a bladder catheter (not supplied).
Device performance:
Performance tests have been conducted on both non-aged samples that have been aged for 12 months following routine sterilization.
These tests included:
- Air leakage test to demonstrate that there is no leakage between the connections of the Catheter Adaptor components under an air pressure of 0.7 bar for at least 15 min. No failures observed at T0 and T12mo.
- . Catheter Adaptor component disconnection force test – to demonstrate that the disconnection force between the component connections shall not be less than 3.00 kgf at a speed of 500 mm/min and shall have a gluing depth of 8.0 mm. No failures observed at T0 and T12mo.
- Catheter Adaptor component unclogged device test to demonstrate that air bubbles appear in the water bath for at least 15 min. No failures observed at T0 and T12mo.
- Non-Luer universal connector to a bladder catheter to demonstrate that the connection . between the non-Luer universal connector of the Catheter Adaptor and the bladder catheter is sealed to prevent user exposure to hazardous drugs. Testing was carried out in accordance with ISO 8536-4:2010, section 6.11.
- . Chemical resistance test - to demonstrate that the device is compatible with cytotoxic drugs.
5
Image /page/5/Picture/0 description: The image shows two logos side by side. The logo on the left is the word "TEVA" in a stylized, sans-serif font with a light blue color. The logo on the right is on a green background and says "Medical" in a cursive font, with the words "Teva Medical Ltd." in a smaller, sans-serif font below it.
The packaging materials and process for the Catheter Adaptor, together with sterilization method and parameters, are unchanged from those utilized for the TEVADAPTOR® Connecting Set component cleared under K141448.
The subject devices are supplied sterile, with an SAL of 106. The devices are sterilized by ethylene oxide, with the same parameters as the remainder of the TEVADAPTOR® components, as described in K141448 for the predicate device.
In addition, biocompatibility tests have been carried out on the components of the Catheter Adaptor to demonstrate that the three new materials used meet the requirements of ISO 10993 and FDA guidance.
Comparison with predicate device:
The predicate device selected for comparison with the revised TEVADAPTOR® Closed Drug Reconstitution and Transfer System is:
| Predicate Device: | TEVADAPTOR® Closed Drug Reconstitution and Transfer System |
|---|---|
| 510(k) Sponsor: | Teva Medical |
| 510(k) Number: | K141448 |
| Clearance Date: | 23 January 2015 |
| FDA Product Code: | ONB |
| Regulation Name: | Intravascular Administration Set |
| Regulation No: | 880.5440 |
The only difference between the predicate and subject device is the addition of a further TEVADAPTOR® System component, this being the Catheter Adaptor. Specific bench tests have been successfully completed to ensure the Catheter Adaptor connects effectively, without leakage, to the other relevant TEVADAPTOR® components, and to a range of commercially available bladder catheters.
Three new materials are introduced to the TEVADAPTOR® System by the inclusion of the Catheter Adaptor. These materials have been subjected to biocompatibility tests in accordance with the applicable parts of ISO 10993 and FDA guidance for the nature of patient contact and duration of contact, and to tests to demonstrate compatibility with an aggressive solvent commonly used with cytotoxic drugs for bladder treatment.
The Indications for Use statement for the TEVADAPTOR® System with the Catheter Adaptor is unchanged from the predicate, K141448.
A reference device is included within this submision, to provide support for inclusion of a bladder catheter within a submission for a Closed Drug Reconstitution and Transfer System. This reference device is the 'Equashield Closed System drug Transfer Device (CSTD)', cleared by FDA on July 3, 2017, under 510(k) K170706, which includes the 'Catheter Luer Lock Adaptor (LL-1C)' component.
Substantial Equivalence Conclusion:
Based on the performance testing conducted on the Catheter Adaptor, the addition of the Catheter Adaptor to the TEVADAPTOR® System does not raise new types of safety and effectiveness questions. It is concluded that the TEVADAPTOR® System modified by the introduction of the Catheter Adaptor is substantially equivalent to the identified predicate device cleared under K141448, which is already in interstate commerce within the USA.